Respiratory, Infectious Disease and Oncology
The Respiratory, Infectious Disease and Oncology (RIO) Clinical Trials Team conducts clinical trials of new drugs for patients with respiratory conditions such as idiopathic pulmonary fibrosis (IPF) and chronic obstructive pulmonary disease (COPD), as well as respiratory infectious disease and lung cancer. The team also run clinical trials of new vaccines in healthy volunteers.
ARORAGE-1001 - Inhalation Solution in Healthy Subjects and Patients With Inflammatory Lung Disease
ARO-RAGE is being developed as a potential asthma and CF treatment and is intended to reduce inflammation in the airways by blocking and inhibiting an important lung receptor (component) involved in the inflammatory response, known as RAGE (Receptor for Advanced Glycation End-products). By reducing inflammation and improving airflow, ARO-RAGE may be an effective treatment for asthma and CF.
Assessment of airway clearance techniques in adults with bronchiectasis
Feasibility of Electrical Impedance Tomography in assessing short-term effects of airway clearance techniques in adults with bronchiectasis, an observational study.
CIC-E-301: a potential new combination vaccine for COVID-19 and flu
ElevAAte - New Treatment for Adults with Alpha-1 Antitrypsin Deficiency (AATD) Emphysems
Study to compare INBRX-101 to plasma derived A1PI therapy in adults with AATD Emphysema
Nimble - Possible new medicine for Adults and Adolescents with Eosinophilic Asthma
A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype.
PACIFIC-9
A Phase III, double-blind, placebo-controlled, Randomised, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy.
Pilaster - New add on therapy to help treat chronic obstructive pulmonary disease with chronic bronchitis
Evaluate the Efficacy and Safety of 2 Doses of CHF6001 DPI (Tanimilast), as add-on to Maintenance Triple Therapy in Subjects With Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis.
SNDX-6352-0506 - Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Axatilimab is a “monoclonal antibody”, which is an antibody manufactured in a laboratory. It is designed to specifically block a protein believed to be involved in lung fibrosis. By blocking this protein, Axatilimab may slow or stop the progression of IPF.
Teton 2 - New IPF Treatment
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects with IPF
Whistle-PF a new oral treatment for patients with Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis (IPF) or non-IPF Progressive Pulmonary Fibrosis (PPF)